oasis 4 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) doctor-only Size:Semaglutide Regular Subscription (Up to 1.25mg/wk) Thinking about using a

oasis 4 semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) doctor-only Size:Semaglutide Regular Subscription (Up to 1.25mg/wk) Thinking about using a

Thinking about using a GLP-1 for weight loss but worried you'll have to stay on it *forever?* You're not alone. But here's the good news: most people don't stay on GLP-1s long-term

While subsidising treatment for all eligible adults has implications for national healthcare expenditure, overweight and obesity and associated comorbidities already place a significant economic and productivity burden on Australia’s healthcare system, estimated to cost our economy approximately $39 billion annually

doctor-only

Size:Semaglutide Regular Subscription (Up to 1.25mg/wk)

Q10: What is the maximum dose of semaglutide studied